Lung Adenocarcinoma Clinical Trials 2023

What Are Lung Adenocarcinoma Clinical Trials?

Lung Adenocarcinoma is a form of lung cancer that starts in the cells which secrete substances like mucus. It is most common in people who smoke and who have formally smoked. However, it is also the most common lung cancer in people who haven't smoked. It's also more common in women than men.

The clinical trials will help people with this disease, and they can access new medications before they are released to the public. So when you participate in a clinical trial, you will also be helping others with the disease to better and live their lives to the fullest.

Why Is Lung Adenocarcinoma Being Studied Through Clinical Trials?

1 in 17 people in the United States is diagnosed with lung adenocarcinoma. But on the good side, the disease develops on the outer side of the lungs. Therefore it's easy to spot before it can spread further in the patient's body and can further harm.

You can identify this disease by a persistent cough, shortness of breath, and wheezing. Worse symptoms can also include loss of weight and coughing up blood. When these symptoms begin and are ongoing, it's best to see a doctor and get help.

What Are The Types Of Treatments Available For Lung Adenocarcinoma?

Oral Restorative Microbiota Therapy - This trial will study a new drug to treat lung cancer by combining a microbiota drug with chemotherapy. An immunotherapy drug will also be administered with the chemo and micro drug.

NEO-201, in combination with pembrolizumab - In this clinical trial, they will test a new drug for cancer. With how the trial is currently going, it looks promising, and the patients are tolerating the medication. Further study will include enrolling patients with non-small cell lung cancer and a few other types of cancers.

What Are Some Recent Breakthrough Clinical Trials For Lung Adenocarcinoma?

2023 - Association of thyroid transcription factor-1 - In this clinical trial, they studied thyroid association in patients with lung cancer. They found that the patients with TTF-1-positive status who received the ICI monotherapy showed better results than those who received the TTF-1-negative.

2018 - Distinctive features of immunostaining and mutational load - In this clinical trial, they studied immunostaining and mutational load in patients with lung cancer. They found that combining two drugs is crucial to the clinical differential diagnosis of the primary PEACs.

Who Are Some Of The Key Researchers Conducting Lung Adenocarcinoma Clinical Trial Research?

Prof. Tomoya Kawaguchi, Ph,D.

Professor Tomoya Kawaguchi is a part of Osaka City University. He got a Ph.D. in medicine from the same university in 1988. In addition, he also has multiple publications available online. He specializes in various lung cancers and Pulamory diseases.

Katherine Stemmer Frumento

Katherine Stemmer Frumento is an extensive researcher in lung cancers. She worked at Greenwich hospital for 17 years as the Library Director. She started her medical librarian career at the Park City Hospital, where she worked for 13 years.